|
|
| A Full-Service Solution Partner Disrupting the Outsourcing Paradigm | inSeption Group offers a full-service solution designed to disrupt the current outsourcing paradigm, resurrecting a common-sense approach to rebuild business trust and confidence in a client’s selected vendor. Primarily focused on oncology, hematology, neurodegenerative disorders, and rare/orphan disease indications, with a specialization in cell and gene therapy, inSeption has been a solution for its’ clients who have experienced the progressive degradation of today’s outsourcing options. Contact them. |
|
|
|
|
Interius BioTherapeutics' lentiviral gene therapy INT2104, which creates CAR T and CAR NK cells in vivo, headed to clinical trials in Australia where the company dosed a first patient with a B-cell malignancy. CEO Phil Johnson, M.D. gave us a look inside the company's global regulatory strategy. |
|
|
|
|
|
|
|
|
|
|
| RNA Sandbox with Johns Hopkins RNA Innovation Center's Jeff Coller, Ph.D. and Michelle Kim, Ph.D. | Don’t miss this week’s Business of Biotech podcast! We’re joined by Drs. Jeff Coller and Michelle Kim, along with Advancing RNA’s Anna Rose Welch, to discuss the Johns Hopkins University RNA Innovation Center. Learn how this groundbreaking venture supports RNA developers and aspiring business builders with unique resources and opportunities. Tune in to discover the Center’s origins, offerings, and how it’s shaping the future of RNA innovation. |
|
|